Evidence map›Paper›PMID 27836886›Full record

ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2017

Dietary acrylamide and the risk of pancreatic cancer in the International Pancreatic Cancer Case-Control Consortium (PanC4).

C Pelucchi, V Rosato, P M Bracci, D Li, R E Neale, E Lucenteforte, D Serraino, K E Anderson, E Fontham, E A Holly and 8 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 13 institutions in 4 countries.

C PelucchiDepartment of Clinical Sciences and Community Health, University of Milan, Milan.
V RosatoUnit of Medical Statistics, Biometry and Bioinformatics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
P M BracciDepartment of Epidemiology and Biostatistics, School of Medicine, University of California, San Francisco, San Francisco.
D LiDepartment of Gastrointestinal Medical Oncology, M.D. Anderson Cancer Center, University of Texas, Houston, USA.
R E NealePopulation Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
E LucenteforteDepartment of Neurosciences, Psychology, Drug Research and Children's Health, University of Florence, Florence.
D SerrainoUnit of Cancer Epidemiology, CRO Aviano National Cancer Institute, Aviano (PN), Italy.
K E AndersonSchool of Public Health, University of Minnesota, Minneapolis.
E FonthamDepartment of Epidemiology, Louisiana State University Health Sciences Center School of Public Health, New Orleans, USA.
E A HollyDepartment of Epidemiology and Biostatistics, School of Medicine, University of California, San Francisco, San Francisco.
M M HassanDepartment of Gastrointestinal Medical Oncology, M.D. Anderson Cancer Center, University of Texas, Houston, USA.
J PoleselUnit of Cancer Epidemiology, CRO Aviano National Cancer Institute, Aviano (PN), Italy.
C BosettiDepartment of Epidemiology, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.
L StrayerSchool of Public Health, University of Minnesota, Minneapolis.
J SuDepartment of Epidemiology, University of Arkansas for Medical Sciences, Little Rock.
P BoffettaThe Tisch Cancer Institute, Mount Sinai School of Medicine, New York, USA.
E J DuellUnit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
C La VecchiaDepartment of Clinical Sciences and Community Health, University of Milan, Milan.
Centro di Riferimento Oncologico · ITThe University of Texas MD Anderson Cancer Center · USUniversity of California, San Francisco · USUniversity of Milan · ITUniversity of Minnesota · USFondazione IRCCS Istituto Nazionale dei Tumori · ITIcahn School of Medicine at Mount Sinai · USInstitut d'Investigació Biomédica de Bellvitge · ESLouisiana State University Health Sciences Center New Orleans · USMario Negri Institute for Pharmacological Research · ITQIMR Berghofer Medical Research Institute · AUUniversity of Arkansas for Medical Sciences · USUniversity of Florence · IT

Funding

CASE-CONTROL STUDY--PANCREATIC CANCER &AROMATIC AMINESR01CA058697 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI ANDERSON, KRISTIN E · 1993 to 1997
–
6 · The paper itself

Abstract

Background: Occupational exposure to acrylamide was associated with excess mortality from pancreatic cancer, though in the absence of dose-risk relationship. Few epidemiological studies have examined the association between acrylamide from diet and pancreatic cancer risk. Patients and methods: We considered this issue in a combined set of 1975 cases of pancreatic cancer and 4239 controls enrolled in six studies of the Pancreatic Cancer Case-Control Consortium (PanC4). We calculated pooled odds ratios (ORs) and their 95% confidence intervals (CI) by estimating study-specific ORs through multivariate unconditional logistic regression models and pooling the obtained estimates using random-effects models. Results: Compared with the lowest level of estimated dietary acrylamide intake, the pooled ORs were 0.97 (95% CI, 0.79-1.19) for the second, 0.91 (95% CI, 0.71-1.16) for the third, and 0.92 (95% CI, 0.66-1.28) for the fourth (highest) quartile of intake. For an increase of 10 µg/day of acrylamide intake, the pooled OR was 0.96 (95% CI, 0.87-1.06), with heterogeneity between estimates (I2 = 67%). Results were similar across various subgroups, and were confirmed when using a one-stage modelling approach. Conclusions: This PanC4 pooled-analysis found no association between dietary acrylamide and pancreatic cancer.

Indexed as

AcrylamideCase-Control StudiesDietHumansPancreatic NeoplasmsRisk FactorsAcrylamideacrylamidecase–control studiespancreatic neoplasmspooled-analysisrisk factors

Identifiers

PMID27836886
PMCPMC6246541
OpenAlexW2551574462

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.